Xeltis Secures €50 Million for Innovative Hemodialysis Solution
Eindhoven, Wednesday, 3 December 2025.
Xeltis’ new €50 million funding will accelerate the market introduction of aXess, a revolutionary solution for hemodialysis patients, backed by the European Investment Bank and other investors.
Introduction to Xeltis and aXess
Xeltis, a medtech company based in the Netherlands, has secured nearly €50 million in funding to advance its innovative hemodialysis solution, aXess. This substantial investment is led by the European Investment Bank (EIB), which has contributed up to €37.5 million, along with €10 million from existing investors, including Invest-NL and EQT Life Sciences [1][2][3].
The Innovative Technology Behind aXess
The aXess solution is a vascular access conduit for hemodialysis patients, developed using Xeltis’ proprietary Endogenous Tissue Restoration (ETR) platform. This technology encourages the body to form new living tissue, reducing complications often associated with traditional vascular access, such as infections and the need for frequent interventions [1][3].
Clinical Success and Market Readiness
Clinical trials of aXess have demonstrated high durability and significant improvements over standard care, with fewer infections and interventions required [2][3]. These positive outcomes have paved the way for Xeltis to prepare for market introduction, with European and U.S. approvals anticipated in 2026 [3][4].
Impact on Hemodialysis Treatment
The introduction of aXess is expected to transform the standard of care for hemodialysis patients by providing a more reliable and sustainable vascular access solution. This innovation aligns with Xeltis’ mission to improve patient outcomes through advanced medtech solutions, aiming for a broad societal impact by enhancing the quality of life for millions of patients worldwide [1][3][5].